Abstract Summary The National Osteoporosis Guideline Group (NOGG) has revised the UK
guideline for the assessment and management of osteoporosis and the prevention of …

It is estimated that 2% to 3% of the population are currently prescribed systemic or topical
glucocorticoid treatment. The potent anti-inflammatory action of glucocorticoids to deliver …

Glucocorticoids are widely used to suppress inflammation or the immune system. High
doses and long-term use of glucocorticoids lead to an important and common iatrogenic …

Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis
and the resulting fractures cause significant morbidity. Following initiation of oral …

Introduction Corticosteroid-induced osteoporosis (CIO) is the most common type of
secondary osteoporosis, leading to fractures, and increased morbidity and mortality. Source …

Osteoporosis associated with long-term glucocorticoid therapy remains a common and
serious bone disease. Additionally, in recent years it has become clear that more subtle …

Efficient therapies are available for the treatment of osteoporosis. Anti‐resorptive therapies,
including bisphosphonates and denosumab, increase bone mineral density (BMD) and …

Corticosteroid-induced osteoporosis is the most common form of secondary osteoporosis
and the first cause in young people. Bone loss and increased rate of fractures occur early …

It is well known that the underlying mechanisms of osteoporosis in older adults are different
than those associated with estrogen deprivation. Age-related bone loss involves a gradual …

Glucocorticoid‐induced osteoporosis (GIO) is the second most common form of osteoporosis
and is the most common iatrogenic form of the disease. Fractures may occur in 30% to 50 …